Cytosorbents Cor (CTSO)

$CTSO I think I am in love.

D. Boral Capital updates rating for CytoSorbents ( $CTSO ) to Buy, target set at 10.

$CTSO if we do not get FDA and Canadian approval the company is done. I still believe in them but this milestone is key

Wall St is expecting -0.05 EPS for $CTSO Q2 [Reporting 08/07 AMC] http://www.estimize.com/intro/ctso?chart=historical&metric_name=eps&utm_c

$CTSO “there you go, the you go, pills are good, pills are good…”

$CTSO In at $0.8866. Let’s go!

$CTSO …1 million shares traded pre market to end up at par haha

$CTSO lets roll

$CTSO On July 31, 2025, Cytosorbents Corp announced its new studies showcasing the impact of CytoSorb® therapy on sepsis treatment, and a webinar is planned for September 10, 2025, for World Sepsis Day. The event underlines the company's focus on advancing treatment options in critical care.

$CTSO avg vol 43k now vol 900k h 1.23 now 1.02

$CTSO $2 this week

Vycor Medical, Inc. (OTCQB: $VYCO) announced the publication of a new peer-reviewed clinical study on its NovaVision division’s NeuroEyeCoach training program, demonstrating significant benefits for stroke patients recovering from visual disorders in both home and clinic settings. Vycor Medical, Inc. Medical is a B2i Digital Featured Venture Company. See the complete profile at https://b2idigital.com/vycor-medical. The study, published in Springer’s Experimental Brain Research, compared 95 patients who accessed NeuroEyeCoach at home with 31 patients who attended a clinic in Verona, Italy. Both groups demonstrated significant improvements in visual search performance and a reduction in visual disability. There is a significant drive in healthcare systems worldwide to access digital technologies in home settings. NeuroEyeCoach was designed to provide low-cost delivery, allowing for wide access. The purpose of the study was to assess whether there are meaningful differences in the benefits and improvements in patients between a clinic setting and a home setting. Significant findings from the research include: · Both home-based and clinic-based patients showed meaningful improvements. · No significant differences in activities of daily living improvements between home-based and clinic-based settings. · Validates NeuroEyeCoach as an effective tool, whether used clinically or accessed remotely. See Vycor’s press release: https://www.newmediawire.com/news/new-study-on-novavision-s-neuroeyecoach-shows-significant-benefits-for-patients-in-home-or-clinic-setting-7081197. Vycor operates two divisions: Vycor Medical (ViewSite™ Brain Access System for neurosurgery) and NovaVision (vision rehabilitation therapies for stroke/brain injury patients). To learn more, watch a video replay of Vycor Medical’s recent presentation at the Life Sciences Virtual Investor Forum, featuring CEO Peter Zachariou and President David Cantor, available at this link: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/4989844/vycor-medical-inc-otcqb-vyco. Vycor Medical is led by CEO Peter Zachariou, President David Cantor, and CFO Adrian Liddell, each bringing extensive experience in medical technology, business development, and finance. Learn more about Vycor Medical at https://www.vycormedical.com/investment-highlights. For investor inquiries, please contact [email protected]. Disclosure: Management of B2i Digital owns shares of VYCO stock purchased in the open market. This post is not intended to solicit the sale of VYCO or any security, and it is not intended to offer any opinion on VYCO as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the full disclaimer in the Risks and Disclosures section of https://b2idigital.com/featured-companies. $CTSO

$CTSO damn

$CTSO what is happening with employees departures?

D. Boral Capital has updated their rating for CytoSorbents ( $CTSO ) to Buy with a price target of 10.

$CTSO CytoSorbents files appeal with FDA for review of request for DrugSorb-ATR CytoSorbents filed a request for supervisory review - administrative appeal - with the FDA under 21 CFR 10.75, of the De Novo Denial Letter issued on April 25 for CytoSorbents' DrugSorb-ATR Device. DrugSorb-ATR, which previously received Breakthrough Device Designation from the FDA, is designed to reduce the severity of bleeding in patients undergoing coronary artery bypass grafting surgery. CytoSorbents is conducting trials to support FDA marketing approval of DrugSorb-ATR for antithrombotic drug removal during cardiothoracic surgery. The denial letter identified remaining deficiencies that must be addressed before the De Novo Request can be granted and the device authorized for U.S. commercialization. In response, the company engaged with the FDA review team to clarify and discuss the remaining deficiencies and determined that a supervisory review through the administrative appeals process was the best path to resolve the remaining deficiencies. The administrative appeals process allows the Company to engage with upper management of FDA's Center for Devices and Radiological Health in a prescribed procedure that includes a formal hearing, with a final decision typically issued approximately 60 days after the appeal is filed. The company remains confident in receiving a final regulatory decision in 2025.

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Cytosorbents Crp. Is that bullish or bearish? $CTSO #RsiOverbought #NASDAQ

$CTSO: CytoSorbents Reports Strong 1st Quarter 2025 Results https://buff.ly/2GKh8ub

D. Boral Capital has updated their rating for CytoSorbents ( $CTSO ) to Buy with a price target of 10.

$CTSO key is the FDA and Canada approval if this will happen the share price will be in long term by to $10+. During the call yesterday it seemed that Cytosorbens is more less confindent that this will happen.